Page 101 - 《中国药房》2022年22期
P. 101

·循证药学·


          TACE 联合局部消融术治疗不可切除原发性肝癌有效性与安全
          性的网状Meta分析
                                       Δ


          田 塬    1, 2* ,唐贵菊 ,李 波 ,李亚玲 (1.自贡市第四人民医院药剂科,四川 自贡 643000;2.西南医科大学附
                                            2 #
                                    4
                           3
          属医院药学部,四川 泸州 646000;3.资阳市第一人民医院药学部,四川 资阳 641300;4.西南医科大学附属
          医院肝胆外科,四川 泸州 646000)

          中图分类号  R979.1;R454      文献标志码  A      文章编号  1001-0408(2022)22-2779-07
          DOI  10.6039/j.issn.1001-0408.2022.22.19

          摘  要  目的  系统评价经动脉化疗栓塞术(TACE)联合局部消融术治疗不可切除原发性肝癌(PLC)的有效性和安全性,为临床
          合理治疗提供循证参考。方法  计算机检索中国知网、万方数据、维普网、PubMed、Embase、Cochrane图书馆、ClinicalTrials、Web of
          Science、Ovid、SinoMed,收集TACE联合局部消融术(试验组)对比TACE(对照组)的随机对照试验(RCT);筛选文献、提取资料后
          采用Cochrane系统评价员手册5.1.0推荐的偏倚风险评价工具对纳入文献进行质量评价;采用Stata14.0软件进行Meta分析。结
          果  共纳入 39 项 RCT,共计 2 294 例患者,涉及 TACE、TACE+射频消融(RFA)、TACE+微波消融(MWA)、TACE+无水乙醇注射
         (PEI)、TACE+冷冻消融(CRA)、TACE+高强度超声聚焦消融(HIFU)6种干预措施,以及铂类、蒽环类、嘧啶类似物及多肽类4种化
          疗药物。Meta 分析结果显示,客观缓解率方面,以 TACE+RFA、TACE+HIFU、TACE+MWA 较高;1 年生存率方面,以 TACE+PEI、
          TACE+HIFU、TACE+MWA 较高;2 年生存率方面,以 TACE+HIFU、TACE+MWA、TACE+PEI 较高;3 年生存率方面,以 TACE+
          HIFU、TACE+PEI、TACE+RFA较高;安全性方面,以TACE+MWA、TACE+RFA、TACE较高。TACE+MWA中,4种化疗药物的疗效
          比较,差异均无统计学意义(P>0.05)。结论  对于不可切除PLC患者,TACE+MWA的疗效和安全性均较好,为最佳组合;TACE+
          MWA中4种化疗药物的疗效均较好,可个性化选择适宜的化疗药物。
          关键词  原发性肝癌;不可切除;经动脉化疗栓塞术;局部消融术;Meta分析;疗效;安全性

          Network  meta-analysis  for  efficacy  and  safety  of  TACE  combined  with  local  ablation  in  the  treatment  of
          unresectable primary liver cancer
                                                     2
                                   3
          TIAN Yuan ,TANG Guiju ,LI Bo ,LI Yaling(1.  Dept.  of  Pharmacy,  Zigong  Fourth  People’s  Hospital,
                    1, 2
                                           4
          Sichuan Zigong 643000, China;2. Dept. of Pharmacy, the Affiliated Hospital of Southwest Medical University,
          Sichuan  Luzhou  646000,  China;3.  Dept.  of  Pharmacy,  Ziyang  Municipal  First  People’s  Hospital,  Sichuan
          Ziyang  641300,  China;4.  Dept.  of  Hepatobiliary  Surgery,  the  Affiliated  Hospital  of  Southwest  Medical
          University, Sichuan Luzhou 646000, China)

          ABSTRACT   OBJECTIVE To systematically evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE)
          combined with local ablation in the treatment of unresectable primary liver cancer (PLC), and to provide evidence-based reference
          for  rational  clinical  treatment.  METHODS  Retrieved  from  CNKI,  Wanfang  Data,  VIP,  PubMed,  Embase,  Cochrane  Library,
          ClinicalTrials, Web of Science, Ovid and SinoMed, randomized controlled trial (RCT) about TACE combined with local ablation
         (trial  group)  versus  TACE (control  group)  were  collected.  After  screening  the  literature  and  extracting  the  data,  the  bias  risk
          assessment  tool  recommended  by  the  Cochrane  System  Evaluator  Manual  5.1.0  was  used  to  evaluate  the  quality  of  the  included
          literature; Stata14.0 software was used for meta-analysis. RESULTS  A total of 39 RCTs were included, including 2 294 patients,
          involving  6  interventions,  i.e.  TACE,  TACE  +  radiofrequency  ablation (RFA),  TACE  +  microwave  ablation (MWA),  TACE  +
          absolute ethanol injection (PEI), TACE + cryoablation (CRA), TACE + high-intensity ultrasound focused ablation (HIFU), and 4
          chemotherapeutic drugs, i.e. platinum, anthracycline, pyrimidine analogues, and polypeptides. The results of meta-analysis showed
          that  in  terms  of  objective  remission  rate,  TACE+RFA,  TACE+HIFU  and  TACE+MWA  were  higher;  in  terms  of  1-year  survival
          rate,  TACE+PEI,  TACE+HIFU  and  TACE+MWA  were  higher;  in  terms  of  2-year  survival  rate,  TACE+HIFU,  TACE+MWA  and
                                                             TACE+PEI  were  higher;  in  terms  of  3-year  survival  rate,
             Δ 基金项目 国家自然科学基金资助项目(No.81803019)                TACE+HIFU,  TACE+PEI  and  TACE+RFA  were  higher;  in
             * 第一作者 药 师 ,硕 士 。 研 究 方 向 :临 床 药 学 。 E-mail:    terms  of  security, TACE+MWA, TACE+RFA  and TACE  were
          643295494@qq.com                                   higher;  there  was  no  significant  difference  in  the  efficacy  of  4
             # 通信作者 主任药师,硕士。研究方向:临床药学。电话:0830-               chemotherapeutic   drugs   in   TACE+MWA  (P>0.05).
          3165762。E-mail:lylapothecary@swmu.edu.cn           CONCLUSIONS  For  patients  with  unresectable  PLC, TACE+


          中国药房  2022年第33卷第22期                                              China Pharmacy  2022 Vol. 33  No. 22    · 2779 ·
   96   97   98   99   100   101   102   103   104   105   106